Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy.Journal of hematology · 2024
   Article
2. [Analysis of infection in B-cell lymphoma patients treated with BTK inhibitors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
   Article
3. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.Current oncology reports · 2022
   Review
4. BTK Inhibitors Impair Platelet-Mediated Antifungal Activity.Cells · 2022
   Article
5. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.Cancer medicine · 2021
   Article

Corrections and comments

• Comment on
  Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.2020

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as